Pharmacokinetic interaction between amlodipine and irbesartan in beagle dogs
- Author:
Xiang-Ping ZHONG
1
Author Information
1. Shanghai Key Laboratory for Pharmaceutical Metabolites Research
- Publication Type:Journal Article
- From:
Academic Journal of Second Military Medical University
2006;27(7):763-767
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate whether there is pharmacokinetic interaction between amlodipine and irbesarta when they are administered together into beagle dogs. Methods: Six healthy adult beagle dogs were evenly divided into 3 groups according to a self-controlled randomized 2-way crossover design. Animals in 3 groups were given a single oral dose of 5 mg amlodipine powder, 250 mg irbesartan powder and compound powder of amlodipine and irbesartan (containing 5 mg amlodipine and 250 mg irbesartan), respectively. The concentrations of amlodipine and irbesartan in beagle dog plasma were determined at specified time points by HPLC-ESI-MS/MS and HPLC-Fluorescence method, respectively; the pharmacokinetic parameters were calculated subsequently. Results: cmax and AUC0-∞ of amlodipine were (267.63±38.49) ng/ml and (5 648.71±871.68) ng · h/ml when administered alone and were (267.43±37.97) ng/ ml and (5 751.60±924.49) ng · h/ml when combined with irbesartan, respectively. cmax and AUC0-∞ of irbesartan were (2 623.56±198.65) ng/ml and (10 327.53±1 522.58) ng · h/ml when administered alone and were (2 345.61±42.32) ng/ml and (10 217.12±1 239.13) ng • h/ml when combined with amlodipine, respectively. There was no significant difference in cmax and AUC of the 2 drugs when they were used alone or jointly. Conclusion: There is no obvious pharmacokinetic interaction between amlodipine and irbesarta when they are administered jointly into beagle dogs.
